Case Report

Development of Tinnitus at a Low Dose of Sertraline: Clinical Course and Proposed Mechanisms

Christopher W. T. Miller

University of Maryland School of Medicine, Baltimore, MD, USA

Correspondence should be addressed to Christopher W. T. Miller; chmiller@psych.umaryland.edu

Received 13 July 2016; Accepted 25 August 2016

Academic Editor: Philipp Sand

Copyright © 2016 Christopher W. T. Miller. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Serotonin has a role in the filtering of auditory input [1], allowing for appropriate disregarding of trivial sensory input [2], and the development of tinnitus may reflect a disturbance in this function [2]. Serotonergic receptors have been described in the cochlea, originating mainly from the dorsal region of the superior olivary complex [3], and this neurotransmitter seems to have a close correlation with GABAergic and glutamatergic input into the cochlea. In effect, serotonin can hamper the glutamatergic bursts which are observed in cochlear pathology [4]. In terms of the subtypes of serotonin receptors distributed in the cochlea [5], some may have a direct influence on glutamatergic functioning, such as the postsynaptic 5-HT1A receptor, which has a role in inhibiting adenyl cyclase.

While tinnitus can be associated with a withdrawal period from selective serotonin reuptake inhibitors (SSRIs) and these medications (including sertraline) have actually been utilized to treat tinnitus [6] (through enhancement of inhibitory GABAergic interneurons), there is still conflicting evidence on how exactly the serotonergic drugs influence perception and processing of auditory stimuli [7]. This writer reports the case of a patient who developed relatively rapid-onset tinnitus while on a rather low dose of sertraline.

2. Case Presentation

A 50-year-old Caucasian woman presented for management of stress and anxiety. She worked in a busy office and was noticing the pressures of her job were having an effect on her mood, which had become more dysphoric over time; she also described “panic-type” feelings when she was feeling overwhelmed. She described her sleep as fragmented. There were no safety concerns. There was no clear decrease in functionality. She did not have any significant past psychiatric or medical history. She was not actively taking any psychiatric medications. She had been taking aspirin 325 mg once daily for several years (self-initiated and maintained) but had stopped before coming to the clinic (there was no stated reason for discontinuation). There was no significant substance history. Working diagnoses of unspecified depressive disorder and...
unspecified anxiety disorder were established; structured rating scales were not utilized. After discussing our treatment options, as well as their risks and benefits, sertraline 50 mg once daily was started.

The patient reported a positive effect on her mood and anxiety symptoms and reported a near-complete improvement in her anxiety. Approximately five weeks after being treated with this regimen, the patient began to experience bilateral, high-pitched tinnitus, something she had never experienced before. There had been no new additions to her medication regimen or other appreciable changes in well-being. Assessments by her primary care physician and an otolaryngologist yielded negative results. It was not felt that the long-standing treatment with aspirin (which had ended recently) was the culprit for the symptom, as the tinnitus had never been present before. The patient was able to continue working but mentioned that the tinnitus was having a serious impact on her ability to function and enjoy life.

Upon further discussion, it was decided to try to discontinue sertraline. At this point, the patient had been on the medication for around nine weeks. Within a few days of stopping the medication, she noticed the tinnitus beginning to subside, and after around one week it was completely resolved.

3. Discussion

Sertraline has generally not been associated with the development of tinnitus [8], though it has been described during the period of medication withdrawal [9]. A single earlier case report described the development of tinnitus in a patient after sertraline administration. In this case, tinnitus failed to remit after discontinuation but was eventually resolved with the use of mirtazapine [10], suggesting that perhaps this antidepres- sant or one with a similar effect on serotonin subtypes may be considered in cases of tinnitus (i.e., inhibiting 5-HT2A and 5-HT2C). However, given that sertraline has been used successfully as a therapeutic agent for tinnitus [6], the relationship is far from straightforward and the effect is difficult to predict.

In addition to the direct interplay serotonin has with the GABA and glutamate systems, something potentially relevant to this case is that salicylates can activate serotonergic neurons in the dorsal raphe through relays from the dorsal cochlear nucleus [11], thus potentially priming the neurons for an enhanced perception of tinnitus, due to hyperactivity in the dorsal cochlear nucleus, inferior colliculus, and auditory cortex [11, 12].

The distribution of key serotonin receptors has been studied in auditory signal processing. There does seem to be representation of 5-HT1A receptors in the organ of Corti and spiral ganglion [5], as well as 5-HT2A receptors in the auditory cortex [13]. As opposed to the more reliably inhibitory effect of 5-HT1A, the effects of 5-HT2A agonism in cortical areas involved in processing auditory signals may evoke neuronal excitation or inhibition [14, 15], as there is a close correlation with GABAergic interneurons as well as the glutamatergic system [16]. Thus, an overly primed serotonergic pathway may lead to unpredictable sensory filtration of auditory stimuli, which may as a result be enhanced. In addition, 5-HT2C (present on the spiral ganglion [5]) has also been shown to participate in neuronal network excitability, and polymorphism of this receptor has been shown to increase sensitivity to auditory stimuli [2]. In rodents, selective serotonin reuptake inhibitors have been shown to desensitize this receptor over time [17], an effect which may underlie some of the subsequent activating effects through release of norepinephrine and dopamine, but which also has relevance in processing of auditory stimuli.

In conclusion, this case illustrates that there is a finely tuned serotonergic influence on the processing of auditory signals, and there may be enhanced sensitivity and perception to certain stimuli. This writer hypothesizes as well that a priming effect in this patient may have led to disruption of normal hearing and heightened her perception, leading to tinnitus.

Competing Interests

The author declares that there is no conflict of interests regarding the publication of this paper.

References

[1] R. G. Johnson, K. E. Stevens, and G. M. Rose, ”5-Hydroxytryptamine2 receptors modulate auditory filtering in the rat,” Journal of Pharmacology and Experimental Therapeutics, vol. 285, no. 2, pp. 643–650, 1998.
[2] J. J. Simpson and W. E. Davies, ”A review of evidence in support of a role for 5-HT in the perception of tinnitus,” Hearing Research, vol. 145, no. 1-2, pp. 1-7, 2000.
[3] M. V. Bartolomé and P. Gil-Loyzaga, ”Serotonergic innervation of the inner ear: is it involved in the general physiological control of the auditory receptor?” The International Tinnitus Journal, vol. 11, no. 2, pp. 119–125, 2005.
[4] B. Mazurek, T. Stöver, H. Haupt, J. Gross, and A. Szczepk, ”The role of cochlear neurotransmitters in tinnitus,” HNO, vol. 55, no. 12, pp. 964–971, 2007.
[5] C. K. Oh, M. J. Drescher, J. S. Hatfield, and D. G. Drescher, ”Selective expression of serotonin receptor transcripts in the mammalian cochlea and its subdivisions,” Molecular Brain Research, vol. 70, no. 1, pp. 135–140, 1999.
[6] S. Zöger, J. Svedlund, and K.-M. Holgers, ”The effects of serotonin on severe tinnitus suffering—a randomized, double-blind, placebo-controlled study,” Journal of Clinical Psychopharmacology, vol. 26, no. 1, pp. 32–39, 2006.
[7] P. Baldo, C. Doree, R. Lazzarini, P. Molin, and D. J. McFerran, ”Antidepressants for patients with tinnitus,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD003853, 2006.
[8] S. K. Robinson, E. S. Viirre, and M. B. Stein, ”Antidepressant therapy in tinnitus,” Hearing Research, vol. 226, no. 1-2, pp. 221–231, 2007.
[9] F. L. Leiter, A. A. Nierenberg, K. M. Sanders, and T. A. Stern, ”Discontinuation reactions following sertraline,” Biological Psychiatry, vol. 38, no. 10, pp. 694–695, 1995.
[10] ”Tinnitus treatment with mirtazapine,” The Journal of Neuropsychiatry and Clinical Neurosciences, vol. 24, no. 2, p. E36, 2012.
[11] K. K. Caperton and A. M. Thompson, “Activation of serotonergic neurons during salicylate-induced tinnitus,” *The Laryngoscope*, vol. 120, supplement 4, p. S203, 2010.

[12] E. Wallhäuser-Franke, “Salicylate evokes c-fos expression in the brain stem: implications for tinnitus,” *NeuroReport*, vol. 8, no. 3, pp. 725–728, 1997.

[13] E. T. Weber and R. Andrade, “Htr2a gene and 5-HT2A receptor expression in the cerebral cortex studied using genetically modified mice,” *Frontiers in Neuroscience*, vol. 4, article 36, 2010.

[14] G. K. Aghajanian and G. J. Marek, “Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release,” *Brain Research*, vol. 825, no. 1-2, pp. 161–171, 1999.

[15] R. Araneda and R. Andrade, “5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex,” *Neuroscience*, vol. 40, no. 2, pp. 399–412, 1991.

[16] R. L. Jakab and P. S. Goldman-Rakic, “Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex,” *Journal of Comparative Neurology*, vol. 417, no. 3, pp. 337–348, 2000.

[17] L. J. Bristow, D. O’Connor, R. Watts, M. S. Duxon, and P. H. Hutson, “Evidence for accelerated desensitisation of 5-HT(2C) receptors following combined treatment with fluoxetine and the 5-HT(1A) receptor antagonist, WAY 100,635, in the rat,” *Neuropharmacology*, vol. 39, no. 7, pp. 1222–1236, 2000.